Table 4.
State of the art antibody formats and their dependence on Cabilly II and III
| Antibody format | Example | Example configuration | Key IP right | Protected by Cabilly II ? | Protected by Cabilly III ? | |
| Murine Immunoglobulin | IgG | Tositumomab (GSK) | ![]() |
Many | Yes | No, because no human Fc |
| Human, humanized or chimeric Immunoglobulin | IgG | Many | Many | Yes | Yes, because human Fc | |
| F(ab)2 | Many | ![]() |
Many | Yes | Yes | |
| Fab | Many | ![]() |
Many | Yes | Yes | |
| single-chain antibody | scFv | Many | ![]() |
Many | Yes | No, because no Fc |
| Diabodies | scFv(n) | Tandabs (Affirmed) | ![]() |
US2005089519 | Yes | No, because no Fc |
| Nanobodies (single domain antibodies) | VHH | Ablynx | ![]() |
US2003088074 | No, because only HC | No, because only HC |
| Camelid | VHH-(CH2–3)2 | hcIgG | ![]() |
EP0698097 | No, because only HC | No, because only HC |
| Shark | VHH-(CH1–5)2 | IgNAR (AdAlta) | ![]() |
US2009148438 | No, because only HC | No, because only HC |
| Primate IgG | Arana (now Cephalon/Teva) | ![]() |
EP 1945668 | Yes | No, because New World primate framework regions (= no human Fc) | |
| Receptor-Ig fusion protein | (Receptor-CH2-CH3)2 | Etanercept (Pfizer) | ![]() |
US5447851 | No, because no Fv | No, because no Fv |
| Immunotoxin | Different formats | L19-TNFa (Philogen) | ![]() |
EP1257297 | Depends on the nature of the Immunoglobulin | Depends on the nature of the Immunoglobulin; L19-TNFa has an scFv, thus does not fall under Cabilly III because of the absence of an Fc |










